Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Giorgio Maria Boggia"'
Autor:
Viviana Moschese, Clementina Canessa, Antonino Trizzino, Baldassarre Martire, Giorgio Maria Boggia, Simona Graziani, the SHIFT and IBIS Study Groups
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-8 (2020)
Abstract Background Primary immunodeficiencies (PID) constitute a heterogeneous group of more than 350 monogenetic diseases. PID patients with antibody impairment require lifelong administration of immunoglobulin G replacement therapy, administered e
Externí odkaz:
https://doaj.org/article/6addb4218a504057acf20279a7462796
Autor:
Alessandra Vultaggio, Antonio Pecoraro, Ibis Study Groups, Shift, Giorgio Maria Boggia, Giuseppe Spadaro, Silvia Ricci
Publikováno v:
Clinical Drug Investigation
Background and Objective In recent years, two Italian non-interventional studies evaluated subcutaneous immunoglobulin (SCIG) treatment in patients affected by primary antibody deficiency (PAD). The SHIFT study considered patients who were treated wi
Autor:
Antonio Pecoraro, Antonino Trizzino, Silvia Ricci, Andrea Matucci, Baldassarre Martire, Claudio Pignata, Vera Gallo, Simona Graziani, Valentina Palladino, Viviana Moschese, Alessandra Vultaggio, Chiara Azzari, Giorgio Maria Boggia, Giuseppe Spadaro
Publikováno v:
Journal of Clinical Immunology
Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicent